{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:50:37Z","timestamp":1783471837098,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":1462,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K24DK078772"],"award-info":[{"award-number":["K24DK078772"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.kint.2017.10.024","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T06:09:28Z","timestamp":1515478168000},"page":"560-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient"],"prefix":"10.1016","volume":"93","author":[{"given":"Donald F.","family":"Chute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2017.10.024_bib1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jhep.2014.01.012","article-title":"Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients","volume":"60","author":"Baid-Agrawal","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.kint.2017.10.024_bib2","doi-asserted-by":"crossref","first-page":"c72","DOI":"10.1159\/000089090","article-title":"Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients","volume":"102","author":"Mitwalli","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.kint.2017.10.024_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS","volume":"65","author":"Fissell","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2017.10.024_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2008.06.003","article-title":"Hepatitis C virus and kidney disease","volume":"49","author":"Martin","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.kint.2017.10.024_bib5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.transproceed.2016.02.050","article-title":"Outcomes of renal allograft recipients with hepatitis C","volume":"48","author":"Carpio","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2017.10.024_bib6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ajkd.2003.09.018","article-title":"The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study","volume":"43","author":"Mahmoud","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.10.024_bib8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.kint.2017.10.024_bib9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2017.10.024_bib10","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.10.024_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/lt.24366","article-title":"Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network","volume":"22","author":"Brown","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.kint.2017.10.024_bib12","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2016.12.020","article-title":"Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C","volume":"66","author":"Fern\u00e1ndez","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.kint.2017.10.024_bib13","doi-asserted-by":"crossref","first-page":"c133","DOI":"10.1159\/000085442","article-title":"Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course","volume":"100","author":"Mahmoud","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.kint.2017.10.024_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-6143.2001.10212.x","article-title":"Hepatitis C virus infection and de novo glomerular lesions in renal allografts","volume":"1","author":"Cruzado","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/039139880803100801","article-title":"Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis","volume":"318","author":"Fabrizi","year":"2008","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.kint.2017.10.024_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2017.10.024_bib17","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00007890-199808270-00010","article-title":"Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years","volume":"66","author":"Hanafusa","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","article-title":"Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients","volume":"65","author":"Legendre","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-6143.2004.00652.x","article-title":"Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list","volume":"5","author":"Bloom","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/j.ajkd.2008.08.005","article-title":"KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD","volume":"52","author":"Gordon","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.10.024_bib22","doi-asserted-by":"crossref","first-page":"e90611","DOI":"10.1371\/journal.pone.0090611","article-title":"Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis","volume":"9","author":"Wei","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.10.024_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.kint.2017.10.024_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0272-6386(03)00422-0","article-title":"Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology","volume":"42","author":"Kamar","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.10.024_bib25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.TP.0000128911.87538.AA","article-title":"Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C","volume":"78","author":"Fontaine","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib26","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2017.10.024_bib27","doi-asserted-by":"crossref","unstructured":"de L\u00e9dinghen v, Laforest C, H\u00e9doze C, et al. Retreatment with sofosbuvir plus grazoprevir\/elbasvir plus ribavirn of patients with hepatitis c virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/cix916.","DOI":"10.1093\/cid\/cix916"},{"key":"10.1016\/j.kint.2017.10.024_bib28","first-page":"1","article-title":"Sofosbuvir\/Velpatasvir\/Voxilaprevir for 12 weeks as a Salvage regimen in NS5A inhibitor-experienced patients with genotype 1\u20136 infection: the phase 3 POLARIS-1 study","volume":"64","author":"Bourliere","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2017.10.024_bib29","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: http:\/\/www.hcvguidelines.org. Accessed June 16,\u00a02017."},{"key":"10.1016\/j.kint.2017.10.024_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir\u2013sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166.2","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2017.10.024_bib31","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0168-8278(17)30444-0","article-title":"LBO-03-MAGELLAN-2: safety and efficacy of glecaprevir\/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1\u20136 infection","volume":"66","author":"Reau","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.kint.2017.10.024_bib32","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib33","first-page":"e890","article-title":"Early results of pilot study using hepatitis C virus (HCV) positive kidneys to transplant HCV infected patients with end-stage renal disease allowing for successful interferon-free direct acting antiviral therapy after transplantation","volume":"8","author":"Gallegos-Orozco","year":"2016","journal-title":"Cureus"},{"key":"10.1016\/j.kint.2017.10.024_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/tri.12954","article-title":"Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study","volume":"30","author":"Bhamidimarri","year":"2017","journal-title":"Transplant Int"},{"key":"10.1016\/j.kint.2017.10.024_bib35","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"16","author":"Kamar","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib36","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/TP.0000000000001618","article-title":"Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents","volume":"101","author":"Lubetzky","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib37","doi-asserted-by":"crossref","first-page":"e0158431","DOI":"10.1371\/journal.pone.0158431","article-title":"Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.10.024_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12664-017-0745-5","article-title":"Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.kint.2017.10.024_bib39","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/TP.0000000000001414","article-title":"Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients","volume":"101","author":"Eisenberger","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12941","article-title":"Ledipasvir\/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus","volume":"31","author":"Morales","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1432-2277.2009.01025.x","article-title":"No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients","volume":"23","author":"Nicot","year":"2010","journal-title":"Transplant Int"},{"key":"10.1016\/j.kint.2017.10.024_bib42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1034\/j.1600-6143.2003.00057.x","article-title":"Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance","volume":"3","author":"Cruzado","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib43","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/01.ASN.0000079613.81511.3C","article-title":"Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation","volume":"14","author":"Kamar","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.10.024_bib44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2017.10.024_bib45","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2017.10.024_bib46","first-page":"470A","article-title":"RUBY-II: efficacy and safety of a ribavirin-free ombitasvir\/paritaprevir\/ritonavir+\/-dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotypes 1a or 4 infection","volume":"63","author":"Gane","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2017.10.024_bib47","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/TP.0000000000001410","article-title":"Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation","volume":"101","author":"Sawinski","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib48","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/TP.0000000000000479","article-title":"Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C\u00a0virus+ renal allografts","volume":"99","author":"Scalea","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2017.10.024_bib49","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/j.kint.2017.10.024_bib50","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib51","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.10.024_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2017.10.024_bib53","first-page":"7629318","article-title":"Atherosclerosis as extrahepatic manifestation of chronic infection with hepatitis C virus","volume":"2016","author":"Voulgaris","year":"2016","journal-title":"Hepat Res Treat"},{"key":"10.1016\/j.kint.2017.10.024_bib54","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1097\/01.ASN.0000145439.48387.BF","article-title":"Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C\u00a0virus","volume":"15","author":"Abbott","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.10.024_bib55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.10.024_bib56","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.29125","article-title":"Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474. R1)","volume":"66","author":"Hogan","year":"2017","journal-title":"Hepatology"},{"issue":"suppl 3","key":"10.1016\/j.kint.2017.10.024_bib57","article-title":"EXPANDER-1: Exploring renal transplants using hepatitis-C Infected donors for HCV-negative recipients","volume":"17","author":"Durand","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2017.10.024_bib58","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/S0168-8278(15)30147-1","article-title":"LO1: Safety of ombitasvir\/paritaprevir\/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study","volume":"62","author":"Pockros","year":"2015","journal-title":"J\u00a0Hepatol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817308074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817308074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T01:23:17Z","timestamp":1646184197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253817308074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0085253817308074"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2017.10.024","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2017.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}